A Phase 1 interventional study of MCI-186 and MCI-186 in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Shionogi · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the effect of MCI-186 on the QT interval corrected for heart rate using Fridericia's formula (QTcF)
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment A, then Treatment C, then Treatment B (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
Drug: MCI-186 · Drug: Placebo
Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment B, then Treatment A, then Treatment C (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
Drug: MCI-186 · Drug: Placebo
Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment C, then Treatment B, then Treatment A (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
Drug: MCI-186 · Drug: Placebo
A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
Also known as: Edaravone
A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
Also known as: Edaravone
A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
Change From Baseline in QTcF(ΔQTcF) With Placebo Adjustment (ΔΔQTcF) at Cmax of MCI-186
The primary outcome endpoint was based on an analysis of the regression relationship between ΔQTcF and the concentration of MCI-186 at matching times post-dose, including adjustment for placebo treatments.
Time frame: 45 min pre-dose to 24 h post-dose
Change From Baseline of Heart Rate(HR) by Timepoint
Time frame: Pre-dose to 24h post-dose
Change From Baseline of PR Interval by Timepoint
Time frame: Pre-dose to 24h post-dose
Change From Baseline of QRS Interval by Timepoint
Time frame: Pre-dose to 24h post-dose
Change From Baseline of QTcF by Timepoint
Time frame: Pre-dose to 24h post-dose
Plasma Concentration of MCI-186
Time frame: Pre-dose to 24h post-dose
Pharmacokinetic(PK) Parameters - Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC 0-inf) of MCI-186
Time frame: Pre-dose to 24h post-dose
PK Parameters - Maximum Plasma Concentration (Cmax) of MCI-186
Time frame: Pre-dose to 24h post-dose
Number of Participants With Adverse Events (AEs)
Time frame: Day 1 to 9
| Milestone | Sequence 1 (Treatment A, Then Treatment C, Then Treatment B) | Sequence 2 (Treatment B, Then Treatment A, Then Treatment C) | Sequence 3 (Treatment C, Then Treatment B, Then Treatment A) |
|---|---|---|---|
| Started | 9 | 9 | 9 |
| Completed | 8 | 8 | 9 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
The primary outcome endpoint was based on an analysis of the regression relationship between ΔQTcF and the concentration of MCI-186 at matching times post-dose, including adjustment for placebo treatments.
| ms | MCI-186 60mg | MCI-186 300mg |
|---|---|---|
| Change From Baseline in QTcF(ΔQTcF) With Placebo Adjustment (ΔΔQTcF) at Cmax of MCI-186 | -0.5 (-1.5 to 0.5) | 0.5 (-1.0 to 1.9) |
| beats per minute | MCI-186 60mg | MCI-186 300mg | Placebo |
|---|---|---|---|
| 30min | 0.2 ± 2.90 | -0.2 ± 2.47 | 0.1 ± 2.59 |
| 60min | 0.6 ± 3.21 | 1 ± 3.08 | 0.8 ± 3.02 |
| 75min | 1 ± 3.43 | 1.1 ± 3.14 | 1.1 ± 3.26 |
| 90min | 0.4 ± 3.17 | 1.8 ± 3.63 | 1.6 ± 3.81 |
| 105min | 0.6 ± 3.27 | 3.1 ± 3.55 | 1.8 ± 3.91 |
| 2hr | 1.7 ± 3.56 | 3.4 ± 3.24 | 3.4 ± 3.8 |
| 3hr | 1.8 ± 4.01 | 4 ± 3.69 | 2.6 ± 3.44 |
| 4hr | 2.1 ± 4.28 | 3.8 ± 4.22 | 3.1 ± 4.57 |
| 6hr | 7.6 ± 4.69 | 9.3 ± 5.18 | 9.1 ± 4.13 |
| 8hr | 8.1 ± 5.44 | 10.2 ± 6.26 | 10.3 ± 7.34 |
| 12hr | 7.1 ± 4.8 | 9.1 ± 6.77 | 7.4 ± 5.83 |
| 24hr | 1.1 ± 4.52 | 4.6 ± 6.9 | 2.7 ± 4.01 |
| msec | MCI-186 60mg | MCI-186 300mg | Placebo |
|---|---|---|---|
| 30min | -0.4 ± 3.72 | 0 ± 6.14 | -1 ± 6.29 |
| 60min | -2.1 ± 3.74 | -0.3 ± 6.79 | -1.4 ± 5.93 |
| 75min | -2.2 ± 4.43 | -1.8 ± 5.53 | -2.5 ± 4.68 |
| 90min | -2.3 ± 4.29 | -2.4 ± 6.81 | -2.8 ± 4.91 |
| 105min | -1.1 ± 4.17 | -2.2 ± 7.91 | -3.1 ± 5.51 |
| 2hr | -2.8 ± 4.51 | -3.2 ± 7.96 | -2.3 ± 7.2 |
| 3hr | -4 ± 6.05 | -5.1 ± 7.34 | -1.7 ± 6.46 |
| 4hr | -4.6 ± 5.81 | -6.4 ± 7.6 | -3.4 ± 5.99 |
| 6hr | -4.2 ± 5.99 | -5.9 ± 8.36 | -5.3 ± 8.64 |
| 8hr | -7.3 ± 6.01 | -7.8 ± 8.58 | -7.9 ± 7.49 |
| 12h | -2.4 ± 7.96 | -5.5 ± 10.72 | -3.5 ± 9.46 |
| 24hr | 1.4 ± 6.87 | -1 ± 7.73 | -0.6 ± 7.16 |
| msec | MCI-186 60mg | MCI-186 300mg | Placebo |
|---|---|---|---|
| 30min | 3.4 ± 5.03 | 3.4 ± 3.53 | 3.4 ± 3.65 |
| 60min | 4.7 ± 3.54 | 5 ± 5.23 | 4.1 ± 3.95 |
| 75min | 4.1 ± 5.02 | 4.1 ± 3.86 | 3.6 ± 3.98 |
| 90min | 3.5 ± 3.61 | 3.5 ± 4.4 | 3.2 ± 4.13 |
| 105min | 3.2 ± 3.94 | 3.2 ± 3.64 | 2.9 ± 4.45 |
| 2hr | 1.4 ± 3.35 | 2.1 ± 4.62 | 1.9 ± 3.85 |
| 3hr | 0.2 ± 4.57 | -0.4 ± 4.47 | 0.1 ± 5.56 |
| 4hr | 0.7 ± 5.47 | -0.6 ± 6.06 | 1.4 ± 5.56 |
| 6hr | -7.3 ± 7.31 | -5.8 ± 7.42 | -4.8 ± 6.48 |
| 8hr | -6.4 ± 7.39 | -6.4 ± 6.63 | -5.5 ± 7.9 |
| 12hr | -6.4 ± 6.26 | -7 ± 7.86 | -4.2 ± 7.99 |
| 24hr | -6 ± 4.15 | -8 ± 5.13 | -5.6 ± 5.06 |
| msec | MCI-186 60mg | MCI-186 300mg | Placebo |
|---|---|---|---|
| 30min | 0.7 ± 1.91 | -1.8 ± 5.06 | 0.2 ± 1.94 |
| 60min | 0.2 ± 1.87 | -0.7 ± 3.62 | -0.1 ± 1.95 |
| 75min | -0.6 ± 1.83 | -1.1 ± 3.59 | -0.7 ± 2.92 |
| 90min | 0.1 ± 2.53 | -1.3 ± 4.15 | -0.9 ± 3.24 |
| 105min | -0.3 ± 2.7 | -1.3 ± 3.41 | -0.8 ± 2.53 |
| 2hr | -0.4 ± 3.28 | -2.1 ± 6.03 | -1.5 ± 3.31 |
| 3hr | 0.3 ± 3.27 | -2 ± 5.31 | -0.4 ± 2.42 |
| 4hr | 0.4 ± 3.08 | -2 ± 5.46 | -1 ± 2.38 |
| 6hr | 1.5 ± 3.17 | 3.5 ± 6.97 | 2.1 ± 4.05 |
| 8hr | 0.6 ± 3.39 | 0.3 ± 5.16 | 0.9 ± 5.32 |
| 12hr | 0.5 ± 3.99 | 0.4 ± 4.14 | 0.9 ± 3.33 |
| 24hr | 0 ± 3.82 | -0.7 ± 5.56 | -0.2 ± 2.9 |
| ng/mL | MCI-186 60mg | MCI-186 300mg |
|---|---|---|
| 30min | 1039 ± 140.0 | 7393 ± 1770 |
| 60min | 791.3 ± 147.0 | 7412 ± 1968 |
| 75min | 454.4 ± 101.6 | 4864 ± 1606 |
| 90min | 308.3 ± 71.22 | 3522 ± 1235 |
| 105min | 227.6 ± 54.48 | 2578 ± 932.7 |
| 2hr | 176.1 ± 43.85 | 1990 ± 733.5 |
| 3hr | 83.60 ± 23.66 | 874.5 ± 326.8 |
| 4hr | 51.28 ± 15.49 | 512.7 ± 197.6 |
| 6hr | 20.39 ± 7.148 | 166.3 ± 69.70 |
| 8hr | 12.34 ± 4.689 | 89.91 ± 39.59 |
| 12hr | 6.522 ± 2.652 | 37.48 ± 16.83 |
| 24hr | 2.684 ± 1.547 | 10.65 ± 4.026 |
| ng·h/mL | MCI-186 60mg | MCI-186 300mg |
|---|---|---|
| Pharmacokinetic(PK) Parameters - Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC 0-inf) of MCI-186 | 1549.22 ± 20.5 | 12916.94 ± 33.3 |
| ng/mL | MCI-186 60mg | MCI-186 300mg |
|---|---|---|
| PK Parameters - Maximum Plasma Concentration (Cmax) of MCI-186 | 1030 ± 14.1 | 7566 ± 25.1 |
| Participants | MCI-186 60mg | MCI-186 300mg | Placebo |
|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 1 | 1 | 1 |
Collected over up to 9 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MCI-186 60mg | 0/27 (0%) | 0/27 (0%) | 1/27 (3.7%) |
| MCI-186 300mg | 0/26 (0%) | 0/26 (0%) | 1/26 (3.8%) |
| Placebo | 0/25 (0%) | 0/25 (0%) | 1/25 (4%) |
| Event | MCI-186 60mg | MCI-186 300mg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 0/27 | 0/26 | 1/25 |
| GastroenteritisInfections and infestations | 0/27 | 1/26 | 0/25 |
| PharyngitisInfections and infestations | 1/27 | 0/26 | 0/25 |
| Age, Continuous(years) | Sequence 1 (Treatment A, Then Treatment C, Then Treatment B) | Sequence 2 (Treatment B, Then Treatment A, Then Treatment C) | Sequence 3 (Treatment C, Then Treatment B, Then Treatment A) | Total |
|---|---|---|---|---|
| Mean | 29.3 ± 9.8 | 28.7 ± 10.6 | 33.6 ± 9.8 | 30.5 ± 9.9 |
| Sex: Female, Male(Participants) | Sequence 1 (Treatment A, Then Treatment C, Then Treatment B) | Sequence 2 (Treatment B, Then Treatment A, Then Treatment C) | Sequence 3 (Treatment C, Then Treatment B, Then Treatment A) | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 9 | 9 | 9 | 27 |
| Race (NIH/OMB)(Participants) | Sequence 1 (Treatment A, Then Treatment C, Then Treatment B) | Sequence 2 (Treatment B, Then Treatment A, Then Treatment C) | Sequence 3 (Treatment C, Then Treatment B, Then Treatment A) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 9 | 9 | 9 | 27 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in Oct 2018, 1 month.
Results were first posted in Nov 2024, 6 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone